Erin Trachet
Director of Scientific Engagement TD2 Oncology Bio
Seminars
Wednesday 28th January 2026
Obesity & Immunotherapy: GLP-1R Agonist & Anti-PD-1 Response in the DIO MC38 Model
2:30 pm
Session for TD2 Oncology
- There is robust clinical evidence that ties obesity (BMI ≥30 kg/m²) to a 2 fold higher risk multiple different types of cancer in both men and women
- Obesity driven immunosuppression in the DIO MC38 model results in accelerated tumor growth and improved response to PD-1 blockade compared to lean counterparts
- Semaglutide in DIO MC38-bearing mice induces clinically relevant body weight loss and the in combination with PD-1 resulted significant metabolic changes but also changes in the immune cell population
